Zhibo Zhao

Dr. Zhibo Zhao

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2026 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
ZZZhibo Zhao
Zhibo Zhao
JZJinxiu Zhou
Jinxiu Zhou
SCSi Chen
Si Chen
HAHuiping An
Huiping An
YSYonghou Sang
Yonghou Sang
XZXiaoshuang Zhou
Xiaoshuang Zhou

1 July 2026 in The FASEB Journal
Verified
Journal Article
Open access
ZZZhibo Zhao
Zhibo Zhao
HAHuiping An
Huiping An
YSYonghou Sang
Yonghou Sang
SCSi Chen
Si Chen
JZJinxiu Zhou
Jinxiu Zhou
XZXiaoshuang Zhou
Xiaoshuang Zhou
Maladaptive repair following acute kidney injury (AKI) is an independent risk factor for the progression to chronic kidney disease (CKD). We hypothesize that renal tubular cell senescence and subsequent epithelial‐mesenchymal transition drive maladaptive repair after AKI, ultimately leading to chronic renal fibrosis. We re‐analyzed single‐cell RNA sequencing data (ScRNA‐seq, GSE212273) from kidney tissues post‐IRI. In vivo, we employed unilateral IRI and folic acid models to simulate the AKI to CKD transition. Senolytics or verteporfin were given from Day 3 post‐modeling. In vitro, human renal tubular epithelial (HK‐2) cells were exposed to hydrogen peroxide or TGF‐β. Sustained YAP1 overexpression promoted fibroblast activation and a profibrotic phenotypic shift. AKI induced a sustained increase in YAP1 expression, which was associated with tubular cell senescence and renal interstitial fibrosis. Senolytics effectively suppressed YAP1 activity, renal senescence, and alleviated kidney fibrosis. In vitro, persistent oxidative stress upregulated YAP1 expression and induced cell senescence. Knockdown of YAP1 downregulated Hippo signaling pathway, extracellular matrix reorganization, and reduced cell senescence. Conversely, YAP1 overexpression reversed the anti‐senescence effect of senolytics. Finally, pharmacological inhibition of YAP1/TEAD1 attenuated cell senescence and post‐ischemic renal fibrosis. Our findings indicate that sustained YAP1 overexpression mediates tubular cell senescence, which drives maladaptive kidney repair and facilitates the AKI to CKD transition. Senolytics or verteporfin therapy initiated after the peak of AKI offers a dual benefit: it protects the regenerative capacity of tubular cells and concurrently inhibits YAP1‐driven epithelial‐mesenchymal transition, thereby mitigating the progression of renal fibrosis.

24 September 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
JLJunhu Li
Junhu Li
STShuqin Tang
Shuqin Tang
STShasha Tian
Shasha Tian
DWDongyun Wang
Dongyun Wang
ZWZhijuan Wu
Zhijuan Wu
XZXiaoshuang Zhou
Xiaoshuang Zhou
Background: Ferroptosis has received increasing attention as a regulated cell-death process potentially involved in sepsis-associated acute kidney injury (SA-AKI). However, the structure, development, and thematic evolution of the SA-AKI–ferroptosis literature have not been clearly characterized. This study aimed to map the publication landscape, collaboration patterns, knowledge base, and emerging research themes in this field using bibliometric and science-mapping approaches. Methods: The Web of Science Core Collection (WoSCC) was used as the primary bibliometric database, and PubMed was used as an independent sensitivity check. A revised search strategy linked an SA-AKI concept block with a ferroptosis concept block using the Boolean operator AND, without using GPX4, ACSL4, SLC7A11, or other molecular markers as stand-alone search alternatives. Articles and reviews published from 2016 to 2025 were screened for substantive relevance to both SA-AKI and ferroptosis. The final WoSCC corpus was analyzed using VOSviewer 1.6.21 and CiteSpace 6.4. R2 for publication trends, collaboration networks, keyword co-occurrence, source co-citation, reference co-citation, clustering, timeline visualization, and burst detection. Results: Ninety-four WoSCC articles and reviews were assessed for eligibility, of which 68 were included in the final bibliometric corpus. Eligible publications first appeared in 2021 and increased from 2 publications in 2021 to 32 in 2025, with 50 of 68 publications (73.5%) published during 2024–2025. China contributed to 64 of 68 publications, whereas international collaboration remained limited. After keyword harmonization, 23 keywords entered the co-occurrence analysis; the most frequent were “ferroptosis,” “acute kidney injury,” “sepsis,” and “sepsis-associated acute kidney injury,” with Nrf2, GPX4, lipid peroxidation, oxidative stress, and related regulatory processes also represented. The reference co-citation network comprised 203 nodes and 858 links and formed 9 clusters (modularity Q = 0.5721; weighted mean silhouette S = 0.8355), connecting the clinical and pathophysiologic literature on SA-AKI with foundational ferroptosis biology and more recent SA-AKI-specific mechanistic studies. The co-cited-source network included 43 sources and 903 links. No sustained reference or keyword bursts were detected using a minimum duration of 2 years; only short 2024–2025 signals emerged in sensitivity analyses using a 1-year minimum duration. Conclusion: Research on ferroptosis in SA-AKI represents a relatively young and rapidly expanding literature that is highly concentrated geographically and characterized by limited international collaboration. Current knowledge structures link established ferroptosis biology with SA-AKI-specific experimental studies, while recent keyword patterns emphasize oxidative stress, lipid peroxidation, Nrf2/GPX4-related regulation, and related cellular processes. The limited duration of citation bursts and the predominance of preclinical literature indicate that the field remains in an early stage of development, and bibliometric signals should not be interpreted as evidence of established clinical translation.

26 October 2026 in Cell Biochemistry and Function
Verified
Journal Article
Open access
PDF file
LXLuming Xi
Luming Xi
MBMengqi Bai
Mengqi Bai
JLJunhu Li
Junhu Li
ZZZhibo Zhao
Zhibo Zhao
XZXiaoshuang Zhou
Xiaoshuang Zhou
Cordycepin (COR) exerts pharmacological effects in various diseases, yet its role in tissue repair following acute kidney injury (AKI) remains to be fully elucidated. This study aimed to investigate whether COR delays the progression from acute kidney injury to chronic kidney disease (AKI‐CKD) and to explore its underlying mechanisms. Network pharmacology was employed to identify shared targets among ferroptosis, AKI‐CKD, and COR using multiple databases. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed, followed by molecular docking validation. In vivo, a renal unilateral ischemia–reperfusion (uIRI) mouse model was established in C57Bl/6N mice ( n = 20), randomly divided into four groups ( n = 5 each): Control, CKD model, COR, and CKD + COR. COR (10 mg/kg) or saline was administered intraperitoneally daily for 2 weeks. Renal pathology and fibrosis were assessed via H&E, PAS, and Masson staining; renal function by serum creatinine and proteinuria. In vitro, HK‐2 cells were treated with H 2 O 2 with or without COR, and cell viability was measured by CCK‐8. The Nrf2 inhibitor ML385 was used to verify pathway involvement. The mRNA and protein levels of GPX4, ACSL4, Nrf2, and Hmox1 were determined by qRT‐PCR and Western blot. Cross‐analysis of network pharmocology identified 42 common targets among 459 COR‐related, 843 AKI‐CKD‐related, and 1866 ferroptosis‐related genes. PPI network analysis suggested that TNF, IL6, and Hmox1 are key targets. Enrichment analyses indicated involvement in iron homeostasis and oxidative stress responses. Molecular docking revealed strong binding of COR to Nrf2 and Hmox1 (–8.5 and –6.7 kcal/mol). In vivo, model mice showed elevated serum creatinine and proteinuria, severe tubular damage, and increased fibrosis, all significantly ameliorated by COR. In vitro, H 2 O 2 reduced HK‐2 cell viability, downregulated GPX4, Nrf2, and Hmox1, and upregulated ACSL4; COR reversed these effects and improved cell survival. ML385 partially blocked COR's protective and regulatory effects, confirming Nrf2/Hmox1 pathway dependence. Our finding indicated that COR inhibits ferroptosis via activation of the Nrf2/Hmox1 signaling pathway, thereby attenuating renal injury and fibrosis and slowing AKI‐CKD progression.

9 September 2026 in Healthcare
Verified
Journal Article
Open access
PDF file
XHXiu Huang
Xiu Huang
XRXiya Ren
Xiya Ren
YHYajie Hao
Yajie Hao
LZLimei Zhao
Limei Zhao
ZZZhibo Zhao
Zhibo Zhao
XZXiaoshuang Zhou
Xiaoshuang Zhou
Background: Sleep-related problems are common among patients receiving dialysis for end-stage renal disease (ESRD), while pharmacological management may be complicated by comorbidities, polypharmacy, and altered drug clearance. This systematic review and meta-analysis evaluated the effects of non-pharmacological interventions on sleep-related outcomes, anxiety symptoms, depressive symptoms, and fatigue symptoms in this population. Methods: PubMed, Embase, the Cochrane Library, and Web of Science were searched from inception to February 2026. The prespecified eligibility criterion was restricted to randomized controlled trials (RCTs) involving adults with ESRD receiving hemodialysis or peritoneal dialysis and reporting an eligible sleep-related outcome. One quasi-cluster randomized trial was retained as a documented protocol deviation. Standardized mean differences (SMDs) calculated using Hedges’ g and 95% confidence intervals (CIs) were pooled using random-effects models with restricted maximum-likelihood estimation and the Hartung–Knapp–Sidik–Jonkman adjustment (REML–HKSJ). Risk of bias was assessed using the revised Cochrane Risk of Bias tool for randomized trials (RoB 2), and evidence certainty was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. PROSPERO: CRD420251123449. Results: The 19 RCTs and one quasi-cluster randomized trial contributed an effective sample size of 1294 participants. The pooled estimate favored non-pharmacological interventions for sleep-related outcomes (Hedges’ g = −0.820, 95% CI −1.188 to −0.451; p = 0.0002), with substantial heterogeneity (I2 = 83.1%; τ2 = 0.4879). The 95% prediction interval (PI) ranged from −2.325 to 0.685. The pooled effects on anxiety symptoms (Hedges’ g = −0.29, 95% CI −0.99 to 0.41; p = 0.219), depressive symptoms (Hedges’ g = −0.64, 95% CI −2.32 to 1.04; p = 0.313), and fatigue symptoms (Hedges’ g = −0.41, 95% CI −0.93 to 0.11; p = 0.087) were not statistically significant. Effect estimates differed significantly by comparator type (Q-between = 11.28, df = 2; p = 0.0036). Conclusions: Non-pharmacological interventions may improve sleep-related outcomes in patients receiving dialysis for ESRD. However, substantial heterogeneity and a prediction interval crossing the null value limit confidence in the pooled estimate. Current evidence does not demonstrate clear benefits for anxiety symptoms, depressive symptoms, or fatigue symptoms.